Updated:
Apixio
Apixio applies machine learning and NLP to unstructured medical records, serving US health plans and providers for risk adjustment and value-based care.
Apixio
Apixio was founded to address a structural problem in US healthcare: critical patient data is locked in unstructured formats such as physician notes, PDFs, and scanned records. The company's AI-driven platform ingests these documents and converts them into structured, actionable data for risk adjustment, quality reporting, and value-based care programs. Per public record, Apixio's technology is deployed by multiple health plans and provider organizations. Apixio's strategy centers on machine learning and natural-language processing applied to clinical data. The platform targets the Medicare Advantage market, where accurate risk-adjustment coding directly affects plan reimbursement. It competes in the healthcare AI sector alongside firms like Innovaccer and Cerner, though its core differentiator is the depth of its NLP capability on legacy documents. The company has not publicly disclosed its funding history or client count, but its product is commercially available to US health plans. The firm is headquartered in San Mateo, California, with no publicly listed additional offices. Apixio has not disclosed its number of employees or named its executive team in public filings. No recent operational event—such as a funding round, acquisition, or product launch—has been reported in the last 24 months that Altss can verify. Apixio's structural differentiator is its focus on converting unstructured healthcare data into structured outputs for risk adjustment, a narrowly specific vertical within health IT. This specialization, combined with the use of proprietary NLP models trained on medical records, gives the company a niche in the growing market for value-based care analytics. Its dependence on Medicare Advantage customers ties its fortunes to US federal healthcare policy.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Mateo
Corporate office
San Mateo, CA, United States
Sector focus
Frequently asked questions
What does Apixio's platform do?
Apixio uses artificial intelligence, specifically natural-language processing and machine learning, to extract structured clinical data from unstructured medical documents such as physician notes, PDFs, and scanned records. This data is used for risk adjustment, care management, and quality reporting for health plans and providers.
Which healthcare sector does Apixio focus on?
Apixio targets the Medicare Advantage market, where its risk-adjustment technology helps health plans code accurately for patient conditions, directly impacting reimbursement from the Centers for Medicare & Medicaid Services (CMS). Its NLP models are tailored to interpret clinical notes and claims data.
Who are Apixio's competitors?
Apixio competes with larger health IT firms such as Innovaccer, Cerner (Oracle Health), and other providers of healthcare AI and risk-adjustment analytics. Its differentiator is its specialized NLP capability for unstructured data, rather than a broader electronic health record platform.
Has Apixio disclosed its funding or ownership?
Apixio has not publicly disclosed its venture funding rounds, investors, or ownership structure. The firm operates as a private company and does not list its board or principal investors on its website or in public filings as of Altss's latest review.
Does Apixio operate outside the United States?
There is no public evidence that Apixio operates outside the United States. Its headquarters is in San Mateo, California, and its product and client base appear to be entirely domestic, focused on US health plans and Medicare Advantage.
What is Apixio's product deployment model?
Apixio offers a software-as-a-service (SaaS) platform, according to its public description. The AI processes data in the cloud, and output is typically integrated into existing health plan workflows. No on-premises deployment or hardware sales have been disclosed.
How does Apixio differentiate from generic NLP tools?
Apixio trains its NLP models on medical-specific vocabularies and coding standards, such as ICD-10 and HCC (Hierarchical Condition Categories). This domain specialization allows it to extract clinically relevant data for risk adjustment, which generic NLP tools are less suited for.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: